Glucagonoma natural history, complications and prognosis: Difference between revisions
Line 9: | Line 9: | ||
*If left untreated, patients with glucagonoma may progress to develop [[necrolytic migratory erythema]], [[cheilosis]], [[stomatitis]], [[diarrhea]], [[polyuria]], and [[polydipsia]]. | *If left untreated, patients with glucagonoma may progress to develop [[necrolytic migratory erythema]], [[cheilosis]], [[stomatitis]], [[diarrhea]], [[polyuria]], and [[polydipsia]]. | ||
* | *Glucagonoma have a very slow growth rate compared to most malignant tumors. | ||
==Prognosis== | ==Prognosis== |
Revision as of 15:29, 16 October 2015
Glucagonoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Glucagonoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Glucagonoma natural history, complications and prognosis |
FDA on Glucagonoma natural history, complications and prognosis |
CDC on Glucagonoma natural history, complications and prognosis |
Glucagonoma natural history, complications and prognosis in the news |
Blogs on Glucagonoma natural history, complications and prognosis |
Risk calculators and risk factors for Glucagonoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia. The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10 year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis.
Natural History
- If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia.
- Glucagonoma have a very slow growth rate compared to most malignant tumors.
Prognosis
For approximately 60% of these tumors are cancerous, the prognosis of glucagonoma depends on the following:
- Whether or not the tumor can be removed by surgery
- The stage of the tumor, the size of the tumor, whether the cancer has spread outside the pancreas
- The patient’s general health
- Whether the tumor has just been diagnosed or has recurred
- The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10 year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis
References